Behr Syndrome: Comprehensive Disease-Characteristics Report

Scope and evidence date. This report treats “Behr syndrome” in its modern, molecularly resolved sense: a severe, usually childhood-onset biallelic OPA1-related neuro-ophthalmologic disorder. Historical use was phenotype-based and can encompass genetically distinct “Behr-like” disorders. Most evidence comes from aggregated disease resources, small case series, individual patients, and OPA1 cellular/animal models—not EHR-scale cohorts or randomized Behr-specific trials.

Executive summary

Behr syndrome is a very rare Mendelian mitochondrial-neurodegenerative syndrome characterized by early bilateral optic atrophy followed or accompanied by cerebellar ataxia, pyramidal signs/spasticity, peripheral neuropathy, and variably developmental, auditory, gastrointestinal, muscular, and cerebral abnormalities. Current disease-resource evidence maps it to MONDO:0008858 and strongly associates it with OPA1; Open Targets reports an association score of 0.812 and cites genetic evidence including PMID 27604308, 17722006, 28494813, 24970096, 11017079, 27150940, 11017080, 25012220, and 35741767. (OpenTargets Search: Behr syndrome)

The mechanistic core is failure of OPA1-dependent inner-mitochondrial-membrane fusion and crista organization, producing mitochondrial fragmentation, respiratory dysfunction, impaired mtDNA maintenance, disturbed calcium/redox homeostasis, excessive mitophagy or apoptosis, and preferential degeneration of metabolically demanding long-projecting neurons—especially retinal ganglion cells. No approved disease-modifying therapy or Behr-specific treatment trial exists; current care is multidisciplinary and supportive. Trials of the oligonucleotide PYC-001 concern dominant OPA1 haploinsufficiency and expressly exclude ADOA-plus phenotypes, so they should not be represented as Behr-syndrome trials. (NCT06970106 chunk 1, NCT06970106 chunk 2, NCT06461286 chunk 1, NCT06461286 chunk 2)

1. Disease information

Definition and nosology

Behr syndrome is a syndromic hereditary optic neuropathy in which childhood optic atrophy occurs with spinocerebellar degeneration, pyramidal-tract dysfunction, and peripheral neuropathy. A current review describes it as childhood-onset optic atrophy with “ataxia and pyramidal signs including spasticity, weakness, and hyperreflexia.” (ojaimi2022mitochondrialfissionand pages 7-8)

Key identifiers

• MONDO: MONDO:0008858.
• OMIM/MIM: 210000.
• Causal-gene resource mapping: OPA1, Ensembl ENSG00000198836; approved name “OPA1 mitochondrial dynamin like GTPase.” (OpenTargets Search: Behr syndrome)
• MeSH: no retrieved disease-specific descriptor; broader applicable descriptors include Optic Atrophies, Hereditary (D015418), Optic Atrophy (D009896), and Mitochondrial Diseases (D028361). (NCT06461286 chunk 2)
• ICD-10/ICD-11: no uniquely validated Behr-syndrome code was identified. Coding generally falls under hereditary optic atrophy/optic-nerve or mitochondrial disease categories; local coding should not be treated as molecularly specific.
• Orphanet: a reliable disease-specific ORPHA number was not recovered from the available evidence and should be curator-verified rather than inferred.

Synonyms/labels: Behr’s syndrome; complicated hereditary infantile optic atrophy; complicated optic atrophy; OPA1-related Behr syndrome; Behr-related syndrome; recessive/compound-heterozygous OPA1 optic atrophy. “DOA-plus” overlaps phenotypically but generally refers to multisystem disease from monoallelic OPA1 variants and is not always equivalent.

Important terminology warning: OPA3-related Costeff syndrome—3-methylglutaconic aciduria type III—is a close differential, not a strict synonym. OPA3 can also cause dominant optic atrophy-cataract-plus disease. Primary literature supporting OPA3 phenotypes includes PMID 15342707, 22797356, 24136862, and 28050599. (weisschuh2021mutationspectrumof pages 17-18)

2. Etiology, causal factors, and risks

Genetic cause

The established cause is biallelic germline pathogenic variants in OPA1, usually compound heterozygous and less commonly homozygous, producing autosomal-recessive disease. By 2011, 14 affected individuals from 13 families carrying compound-heterozygous or homozygous OPA1 variants had been documented. The first molecularly defined case, reported in 2001, carried two heterozygous missense variants in exon 8. (nottia2021mitochondrialdynamicsmolecular pages 8-10)

OPA1 variants across the broader disease spectrum include missense, nonsense, frameshift, splice-altering, and copy-number alleles. In a 755-proband optic-atrophy cohort, 278 probands (36.8%) had putatively pathogenic OPA1 variants; 156 unique variants were found, 78% were null alleles, and c.2708_2711del/p.(Val903Glyfs3) represented 14% of disease-causing alleles. These are OPA1-spectrum statistics*, not Behr-specific frequencies. The study classified nine novel variants as pathogenic, 34 as likely pathogenic, and five as VUS. DOI: https://doi.org/10.1371/journal.pone.0253987, published 9 July 2021. (weisschuh2021mutationspectrumof pages 17-18)

A typical recessive genotype combines a severe loss-of-function allele with a hypomorphic missense allele; two severe alleles can cause a much more severe mitochondrial encephalomyopathy, sometimes with cardiomyopathy, lactic acidemia, and death. Variant interpretation must therefore be allele- and phase-specific. Homozygous or compound severe alleles should not automatically be equated with the survivable classic Behr phenotype. (nottia2021mitochondrialdynamicsmolecular pages 8-10)

All established causal variants are constitutional/germline. Somatic mutation is not a recognized Behr mechanism. Population allele frequency must be checked variant-by-variant in gnomAD/TOPMed; no defensible aggregate carrier frequency was found. Pathogenic recessive alleles are expected to be rare, and an allele too frequent for this ultra-rare phenotype requires reassessment.

Environmental, lifestyle, infectious, and protective factors

No environmental toxin, infection, diet, occupation, smoking pattern, sex, or lifestyle exposure is established as a cause or penetrance determinant. No validated protective genetic allele, dietary factor, or gene-environment interaction has been demonstrated specifically for Behr syndrome. General mitochondrial-health advice—avoid smoking, excessive alcohol, malnutrition, and unnecessary mitochondrial-toxic drugs—is prudent but not proven to alter this disease’s natural history.

Family history, parental consanguinity, and ancestry can increase the prior probability of recessive disease but are not biological causes independent of genotype. No robust founder effect, anticipation, germline-mosaicism rate, or sex bias has been established.

3. Phenotypes

The phenotype is highly variable, and Behr-specific percentages are generally unavailable because published cohorts are very small.

• Bilateral optic atrophy/optic neuropathy—usually infancy or childhood onset, progressive and irreversible; impaired acuity, color vision, central/centrocecal field loss, and later severe visual disability. Suggested HPO: HP:0000648.
• Ataxia/spinocerebellar degeneration—childhood or later, generally progressive; dysmetria, dysdiadochokinesia, nystagmus, and gait instability. HPO: HP:0001251; dysmetria and nystagmus may be separately encoded.
• Pyramidal signs—spasticity, hyperreflexia, weakness, and sometimes extensor plantar responses; progressive mobility limitation. HPO: HP:0001257 and relevant hyperreflexia terms.
• Peripheral neuropathy/posterior-column dysfunction—sensory loss, weakness, areflexic components, pes cavus, and contractures. HPO: HP:0009830, HP:0001761.
• Developmental delay/hypotonia—particularly in severe early-onset disease; delayed motor milestones may precede gait decline. HPO: HP:0001263, HP:0001252.
• Hearing impairment, often sensorineural; HPO: HP:0000365.
• Dysarthria and dysphagia; HPO: HP:0001260, HP:0002015.
• Gastrointestinal dysmotility—vomiting, constipation, dysphagia, and feeding difficulty.
• Musculoskeletal manifestations—pes cavus and severe lower-limb contractures.
• Severe-variable manifestations—lactic acidemia, myopathy, cardiomyopathy, developmental encephalopathy, and Leigh-like episodes have occurred in the most severe biallelic disease. (ojaimi2022mitochondrialfissionand pages 7-8, nottia2021mitochondrialdynamicsmolecular pages 8-10)

MRI can show optic-nerve/chiasm atrophy, cerebellar or vermian atrophy (HP:0001272), periventricular white-matter abnormalities, and occasionally Leigh-like basal-ganglia hyperintensities with lactate accumulation. (ojaimi2022mitochondrialfissionand pages 7-8, nottia2021mitochondrialdynamicsmolecular pages 8-10)

Quality-of-life impact

No Behr-specific EQ-5D, SF-36, PROMIS, or utility study was identified. Expected burden is substantial: visual impairment limits reading, education, orientation, and driving; ataxia/spasticity/neuropathy impair walking and self-care; hearing loss and dysarthria impair communication; dysphagia and contractures add aspiration, nutrition, pain, and caregiver burdens. These effects are clinically plausible but have not been quantified with a validated Behr-specific instrument.

4. Genetic and molecular information

OPA1 encodes a ubiquitously expressed dynamin-like GTPase localized to the mitochondrial inner membrane. More than 500 OPA1 variants had been described in a 2024 review; the two principal mechanisms across dominant disease are haploinsufficiency and dominant-negative interference. Splice/deletion null alleles often cause haploinsufficiency, whereas some missense alleles exert stronger functional effects. Compound heterozygosity can shift disease from isolated dominant optic atrophy to early multisystem Behr syndrome. (lee2024hereditaryopticneuropathies pages 5-7)

For a knowledge-base entry, each reported allele should include HGVS transcript, genome build, phase, ClinVar accession, ACMG/AMP classification, gnomAD ancestry-specific frequency, and functional assay. VUS should not be promoted to causal without segregation, transcript, protein, or mitochondrial-function evidence. Deep-intronic splice variants and copy-number changes are diagnostically relevant; RNA/minigene analysis may resolve uncertain splice effects.

No reproducible modifier gene is established. Patient-derived neurons carrying the same OPA1 variant can have different clinical severity, but candidate modifiers remain unresolved. Broader OPA1 work reports altered CpG methylation and downregulation of developmental genes in OPA1-haploinsufficient neural progenitors; this is mechanistic model evidence, not a validated Behr epigenetic biomarker. (dotto2021dominantopticatrophy pages 5-6)

No recurrent disease-defining aneuploidy, translocation, inversion, or large chromosomal syndrome is established. Consequently, karyotyping, FISH, and CMA are not first-line unless the phenotype suggests an independent chromosomal diagnosis.

5. Environmental information

No toxin, radiation exposure, pollutant, occupational exposure, lifestyle factor, or infectious agent is known to initiate Behr syndrome. It is not infectious, transmissible, or zoonotic. Evidence for oxidative stress is downstream of inherited mitochondrial dysfunction rather than proof of an environmental etiology. Environmental avoidance recommendations should therefore be labeled precautionary, not disease-preventive.

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic trigger: two functionally damaging OPA1 alleles reduce or qualitatively impair OPA1.
2. Primary organellar defect: impaired inner-membrane fusion, cardiolipin-dependent membrane remodeling, and crista-junction organization cause fragmented mitochondria and disordered cristae.
3. Bioenergetic/quality-control consequences: destabilized respiratory-chain supercomplexes, reduced oxygen consumption/OXPHOS, impaired mtDNA maintenance or depletion, abnormal calcium handling, ROS stress, and altered autophagy/mitophagy.
4. Cell-death and connectivity consequences: cytochrome-c/apoptotic susceptibility, reduced axonal mitochondrial density, defective synaptogenesis, and progressive axonal degeneration.
5. Tissue selectivity: retinal ganglion cells and long central/peripheral neurons have high energy demand and long axons, making them particularly vulnerable; degeneration produces optic atrophy, corticospinal signs, neuropathy, and cerebellar dysfunction. OPA1 also regulates cytochrome-c release and apoptosis. (strachan2025novelinvivo pages 1-2, dotto2021dominantopticatrophy pages 10-11, alavi2013dominantopticatrophy pages 1-3, fogazza2018biochemicalcharacterizationand pages 35-38)

Human cellular and muscle observations include fragmented mitochondrial networks, ragged-red fibers, diminished cytochrome-c oxidase staining, reduced complex-IV activity, and mtDNA depletion in severe disease. (nottia2021mitochondrialdynamicsmolecular pages 8-10, ojaimi2022mitochondrialfissionand pages 7-8)

Suggested GO annotations: mitochondrial inner membrane fusion (GO:0007342), mitochondrial inner membrane (GO:0005743), mitochondrial crista, mitochondrial organization, oxidative phosphorylation, respiratory electron transport, mitochondrial DNA maintenance, mitophagy, intrinsic apoptotic signaling, calcium-ion homeostasis, and response to oxidative stress. Exact current GO IDs beyond those shown should be ontology-version checked.

Suggested cells: retinal ganglion cell (CL:0000704, verify current release), cerebellar neuron/Purkinje cell, corticospinal motor neuron, peripheral sensory neuron, peripheral motor neuron, and skeletal myocyte. Only retinal-ganglion-cell vulnerability is directly and repeatedly demonstrated; other cell assignments partly follow clinical localization.

Molecular profiling and advanced technologies

Metabolomic work in OPA1-disrupted fibroblasts identified a bioenergetic signature including aspartate deficiency; lipidomics found triacylglycerol accumulation from impaired fatty-acid flux. These findings are not validated clinical biomarkers. iPSC lines have been generated directly from a Behr patient for disease modeling (Hauser et al., Stem Cell Research, 2016; DOI https://doi.org/10.1016/j.scr.2016.09.012). Broader OPA1 iPSC neurons exhibit reduced oxygen consumption, complex-I abundance/activity, mitochondrial fragmentation, ROS elevation, impaired axonal mitochondrial distribution, and loss of synaptic contacts. (dotto2021dominantopticatrophy pages 10-11, dotto2021dominantopticatrophy pages 5-6)

No validated Behr-specific single-cell atlas, spatial-transcriptomic signature, plasma proteomic panel, metabolomic diagnostic classifier, or multi-omics prognostic model was identified.

7. Anatomical structures affected

Primary: bilateral retina—especially retinal ganglion-cell layer—and optic nerves/optic chiasm. Neurologic: cerebellum and vermis, corticospinal/pyramidal tracts, posterior columns, peripheral nerves, and variably cerebral white matter/basal ganglia. Secondary/variable: skeletal muscle, auditory pathway, gastrointestinal neuromuscular system, and heart in severe biallelic disease. (ojaimi2022mitochondrialfissionand pages 7-8, nottia2021mitochondrialdynamicsmolecular pages 8-10)

Suggested UBERON terms include retina, retinal ganglion-cell layer, optic nerve, optic chiasm, cerebellum, cerebellar vermis, corticospinal tract, spinal-cord posterior column, peripheral nerve, skeletal muscle, and heart. Exact IDs require release-specific verification. Ocular and neurologic involvement is generally bilateral; asymmetry can occur clinically but unilateral disease would be atypical and should prompt reconsideration.

Subcellular localization is predominantly the mitochondrial inner membrane and cristae; downstream abnormalities involve respiratory-chain complexes, mitochondrial nucleoids/mtDNA, and autophagic/lysosomal pathways.

8. Temporal development

Onset is usually insidious in infancy or childhood. Optic neuropathy and developmental/motor abnormalities often occur first; gait difficulty commonly becomes prominent in the second decade. Rare adult-onset optic atrophy-ataxia presentations are reported. Disease is chronic and generally progressive, not relapsing-remitting. (ojaimi2022mitochondrialfissionand pages 7-8, nottia2021mitochondrialdynamicsmolecular pages 8-10)

A practical—not formally validated—staging framework is:

• Early: reduced visual acuity/color discrimination and optic pallor, sometimes delayed motor development.
• Intermediate: gait ataxia, spasticity/hyperreflexia, neuropathy, dysarthria, and hearing impairment.
• Advanced: severe visual disability, loss of independent ambulation, contractures, dysphagia, and multisystem complications.

No spontaneous remission pattern is established. The most plausible therapeutic window is before irreversible retinal-ganglion-cell and long-tract axonal loss, but this remains a mechanistic inference rather than a proven Behr intervention window.

9. Inheritance and population

Classic molecularly defined OPA1-related Behr syndrome is autosomal recessive. Recurrence risk is 25% per pregnancy when both parents are heterozygous carriers, with a 50% carrier probability and 25% probability of inheriting neither familial allele. Expressivity is variable and depends strongly on allele severity. Penetrance cannot be reliably quantified from available cohorts. Anticipation is not expected because repeat expansion is not the mechanism.

No population-based Behr prevalence or incidence was found. The approximately 1 in 30,000, and in some populations 1 in 12,000, estimates concern autosomal/dominant optic atrophy broadly—not Behr syndrome. Approximately 20% of autosomal optic atrophy cases have extraocular AOA-plus features, again not a Behr-specific statistic. (strachan2025novelinvivo pages 1-2)

No reliable sex ratio, age distribution, carrier frequency, geographic clustering, or ancestry-specific prevalence is available. Consanguinity can enrich homozygosity in individual families, but its population contribution is unquantified.

10. Diagnostics

Clinical evaluation

Diagnosis begins with bilateral optic atrophy plus neurologic examination for ataxia, pyramidal signs, neuropathy, developmental delay, hearing loss, and bulbar or gastrointestinal dysfunction. Recommended investigations include:

• Best-corrected and low-contrast visual acuity, color testing, fundus examination, static perimetry.
• Spectral-domain OCT of retinal nerve-fiber and ganglion-cell layers.
• Visual evoked potentials; ERG when retinal dystrophy is a concern.
• Brain/orbit MRI for optic nerve/chiasm and cerebellar/white-matter abnormalities.
• Audiology, EMG/nerve-conduction studies, gait assessment, and swallowing evaluation as indicated.
• Blood lactate, CK, metabolic panel, and ECG/echocardiography where systemic disease is suspected; normal results do not exclude Behr syndrome.
• Muscle biopsy and respiratory-chain/mtDNA studies are now second-line, useful when sequencing is inconclusive or a severe mitochondrial phenotype requires functional clarification. Trial protocols illustrate current quantitative ophthalmic endpoints, including ETDRS acuity, perimetry, mfVEP, OCT RNFL/GCL, flavoprotein fluorescence, and retinal-apoptosis imaging. (NCT06970106 chunk 2, NCT06461286 chunk 1, NCT06461286 chunk 2)

Genetic testing strategy

1. Use a hereditary optic neuropathy/mitochondrial-neurodegeneration panel including OPA1, with deletion/duplication detection and adequate intronic splice coverage.
2. If unrevealing or phenotype is complex, use trio WES or WGS; broader genomic testing is preferred when no familial variant is known.
3. Confirm both variants, phase them in parents, apply ACMG/AMP criteria, and perform RNA studies for suspected splice variants.
4. mtDNA sequencing is useful for LHON/NARP/Leigh differentials but is not the primary test for OPA1-related Behr syndrome.
5. CMA, karyotype, FISH, and repeat-expansion testing are phenotype-directed, not routine Behr tests. (lee2024hereditaryopticneuropathies pages 5-7)

There are no universally accepted clinical criteria independent of molecular confirmation. Genetic diagnosis is therefore central.

Differential diagnosis

Major alternatives are OPA3/Costeff syndrome, dominant OPA1/DOA-plus, SPG7- and AFG3L2-related optic atrophy/spastic ataxia, MFN2 neuropathy, WFS1 spectrum, ACO2 cerebellar-retinal degeneration, SSBP1 mtDNA-maintenance disease, DNAJC30 recessive LHON, mitochondrial LHON/NARP/Leigh syndromes, Friedreich ataxia, complicated hereditary spastic paraplegias, and leukodystrophies. OPA3 disease is favored by 3-methylglutaconic aciduria and its characteristic genetic/ocular spectrum.

No newborn population screening is established. Cascade testing of relatives and targeted familial-variant testing are appropriate after molecular confirmation.

11. Outcome and prognosis

The usual course is lifelong and progressive. Vision loss generally does not spontaneously recover in OPA1 disease. Neurologic disability can advance from gait difficulty to loss of independent ambulation, with additional morbidity from contractures, falls, hearing loss, dysphagia, aspiration, and nutritional compromise. (lee2024hereditaryopticneuropathies pages 5-7)

No valid 5- or 10-year survival rate, median life expectancy, mortality rate, or Behr-specific quality-of-life statistic exists. Many patients survive into adulthood, but severe homozygous/biallelic mitochondrial encephalomyopathy can include cardiomyopathy and fatal outcomes. Prognosis likely depends on residual OPA1 function, age at onset, neurologic burden, cardiomyopathy/lactic acidosis, swallowing safety, and rate of visual/motor decline, but no validated prognostic model or biomarker exists. (nottia2021mitochondrialdynamicsmolecular pages 8-10)

12. Treatment

Current real-world management

No FDA/EMA-approved pharmacologic, gene, RNA, or cell therapy exists specifically for Behr syndrome. Management is individualized and multidisciplinary:

• Low-vision rehabilitation, optical/electronic aids, educational accommodations, orientation and mobility training.
• Physical and occupational therapy, gait aids, orthoses, stretching, contracture prevention, and fall prevention.
• Symptomatic antispasticity treatment when benefits exceed weakness/sedation risks.
• Speech-language therapy and augmentative communication.
• Audiology and hearing aids/cochlear-implant assessment.
• Swallow evaluation, diet modification, nutrition support, and gastrostomy when clinically necessary.
• Neuropathic-pain treatment, orthopedic management, cardiology surveillance in severe phenotypes, and psychosocial support.

Suggested MAXO concepts include ophthalmologic examination, OCT, visual-field testing, low-vision therapy, physical therapy, occupational therapy, speech therapy, hearing-aid fitting, dysphagia management, enteral feeding, orthotic treatment, and genetic counseling; exact MAXO IDs should be curator-verified.

Idebenone has only weak, uncontrolled evidence in dominant optic atrophy: a small phase-II study reported a statistically significant but minor visual-acuity recovery after 12 months at 900 mg/day, with major limitations from sample size and lack of a control group. It cannot be considered established Behr treatment. (lee2024hereditaryopticneuropathies pages 5-7)

Experimental therapy and trials

NCT06461286 (Sundew) is a first-in-human phase 1a study of one intravitreal PYC-001 dose in approximately 18 adults with confirmed OPA1 haploinsufficiency-associated dominant optic atrophy; it began 31 October 2024 and was active, not recruiting, in the retrieved registry record. PYC-001 is an oligonucleotide therapeutic. Crucially, the protocol excludes ADOA-plus and non-haploinsufficiency mechanisms; therefore Behr patients are not the intended population. Registry URL: https://clinicaltrials.gov/study/NCT06461286. (NCT06461286 chunk 1, NCT06461286 chunk 2)

NCT06970106 (Myrtle) is a phase 1b/1–2 open-label dose study of intravitreal peptide-phosphorodiamidate morpholino PYC-001, estimated enrollment 24, with 10–60 µg single/repeat-dose cohorts. It began 30 September 2025 and was recruiting in the retrieved record. Eligibility again requires dominant OPA1 haploinsufficiency and excludes ADOA-plus/confounding variants. Registry URL: https://clinicaltrials.gov/study/NCT06970106. (NCT06970106 chunk 1, NCT06970106 chunk 2)

Gene augmentation, splice correction, CRISPR repair, iPSC-derived retinal-ganglion-cell replacement, antioxidant treatment, and mitophagy/necroptosis modulation remain preclinical. Their major challenge is the allele-specific combination of one severe and one hypomorphic OPA1 allele and the need to reach both retina and systemic nervous tissue.

13. Prevention

Primary lifestyle prevention and vaccination are not applicable to this inherited disorder. The principal prevention options are reproductive and molecular:

• Genetic counseling and parental phasing.
• Cascade carrier testing of adult relatives.
• Prenatal diagnosis by CVS/amniocentesis when familial pathogenic variants are known.
• IVF with preimplantation genetic testing for monogenic disease.
• Early targeted testing of at-risk siblings to permit surveillance and rehabilitation before major functional loss.

Tertiary prevention includes fall prevention, contracture management, aspiration/nutrition surveillance, hearing and vision rehabilitation, and monitoring for cardiomyopathy or metabolic decompensation in severe cases. Avoiding tobacco, excessive alcohol, and unnecessary mitochondrial toxins is reasonable general advice but is not proven primary prevention.

14. Other species and natural disease

No well-established naturally occurring veterinary disease precisely equivalent to human biallelic OPA1 Behr syndrome was identified. OPA1 is evolutionarily conserved across vertebrates and invertebrate ortholog systems. There is no transmission or zoonotic potential.

OPA3-related natural/model phenotypes should not be merged with OPA1 Behr syndrome. A murine Opa3 missense model reproduces aspects of Costeff syndrome, and zebrafish opa3 models have illuminated metabolic/protective functions, but these model a differential disease mechanism rather than OPA1-related Behr syndrome.

15. Model organisms and experimental systems

• Patient fibroblasts/muscle: mitochondrial fragmentation, COX/complex-IV defects, mtDNA depletion, and abnormal bioenergetics; directly relevant but limited in modeling retinal and long-axon vulnerability.
• Patient-derived iPSCs: an “iPS-OPA1-BEHR” line was generated specifically for complex optic-atrophy/Behr modeling (DOI https://doi.org/10.1016/j.scr.2016.09.012). iPSC neurons enable studies of respiration, ROS, axonal mitochondrial transport, and synaptic degeneration but lack whole-organism natural history. (dotto2021dominantopticatrophy pages 10-11)
• Mouse: heterozygous Opa1 models show age-dependent RGC dysfunction/loss, optic-nerve demyelination/axonal degeneration, mitochondrial ultrastructural abnormalities, and increased autophagy/mitophagy. Homozygous knockout is embryonic lethal, limiting recreation of survivable biallelic Behr disease. (dotto2021dominantopticatrophy pages 5-6)
• Zebrafish: morpholino depletion causes developmental delay, small eyes, reduced circulation and heart rate, mitochondrial fragmentation, and impaired bioenergetics. A recent CRISPR Opa1 knockout produced visual impairment before RGC degeneration, fragmented axonal mitochondria, disordered cristae, and reduced respiration while early locomotion remained relatively preserved. This temporal ordering supports mitochondrial dysfunction as upstream of neuronal loss. DOI https://doi.org/10.1096/fj.202403271R; accepted 19 March 2025. (strachan2025novelinvivo pages 1-2)
• Drosophila: Opa1 deficiency causes reduced survival, visual and cardiac abnormalities, elevated ROS, dysmorphic mitochondria, and age-dependent multisystem disease; useful for genetic and drug screens but anatomically distant from the human optic nerve.
• C. elegans: eat-3 loss causes fragmented mitochondria, abnormal cristae, oxidative-stress sensitivity, progressive movement/neural defects, and altered mitophagy; valuable for pathway interrogation, not direct visual-phenotype modeling. (dotto2021dominantopticatrophy pages 5-6)
• Yeast: MGM1, the OPA1 ortholog, is useful for functional classification of variants and mtDNA-instability assays but cannot model neuronal selectivity.

The strongest cross-model conclusion is that mitochondrial fragmentation and respiratory/visual dysfunction precede overt RGC loss, identifying mitochondrial maintenance as an upstream therapeutic target. Translation remains uncertain because most models represent haploinsufficiency or complete knockout rather than the compound severe-plus-hypomorphic genotype typical of Behr syndrome.

Recent developments and expert assessment

The most consequential 2023–2024 developments were improved broad genomic diagnosis for complex hereditary optic neuropathies, increasing use of RNA/functional assays for splice variants, maturation of patient-specific iPSC systems, and entry of an OPA1-directed oligonucleotide into a 2024 first-in-human dominant-optic-atrophy trial. A 2024 expert review nevertheless concluded that treatment studies remain nascent and that present management is largely supportive. The same review emphasizes that compound-heterozygous OPA1 variants cause the early optic-neuropathy, spinocerebellar, peripheral-neuropathy, pyramidal, and developmental phenotype recognized as Behr-related syndrome. DOI https://doi.org/10.3390/jcto2030006, published June 2024. (lee2024hereditaryopticneuropathies pages 5-7)

A useful exact abstract statement from the 2025 model study is: “mitochondrial disruption and visual impairment precede degeneration of RGCs.” This supports intervention before irreversible ganglion-cell loss but does not establish clinical efficacy. (strachan2025novelinvivo pages 1-2)

A second key exact summary from the modern clinical literature is that Behr syndrome is characterized by “childhood-onset optic atrophy combined with ataxia and pyramidal signs including spasticity, weakness, and hyperreflexia.” (ojaimi2022mitochondrialfissionand pages 7-8)

Ontology-ready summary

The following artifact provides compact annotations and curation caveats.

Table: This compact table summarizes ontology-ready facts for OPA1-related Behr syndrome, including identifiers, inheritance, phenotypes, anatomy, mechanisms, diagnostics, and supportive management. It also flags areas needing curator verification and clearly separates Behr syndrome from OPA3/Costeff syndrome.

Evidence limitations

Behr syndrome has no large registry-quality natural-history cohort, prevalence study, controlled treatment trial, validated quality-of-life instrument, or standardized diagnostic/management guideline. Numerical data from dominant optic atrophy must not be imported as Behr-specific statistics. Likewise, evidence from OPA1 haploinsufficiency models and trials is mechanistically relevant but not automatically applicable to biallelic systemic disease. Variant-level curation should return to primary case reports and ClinVar/gnomAD records before database ingestion.

References

1. (OpenTargets Search: Behr syndrome): Open Targets Query (Behr syndrome, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (NCT06970106 chunk 1): Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle). PYC Therapeutics. 2025. ClinicalTrials.gov Identifier: NCT06970106

3. (NCT06970106 chunk 2): Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle). PYC Therapeutics. 2025. ClinicalTrials.gov Identifier: NCT06970106

4. (NCT06461286 chunk 1): SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew). PYC Therapeutics. 2024. ClinicalTrials.gov Identifier: NCT06461286

5. (NCT06461286 chunk 2): SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew). PYC Therapeutics. 2024. ClinicalTrials.gov Identifier: NCT06461286

6. (ojaimi2022mitochondrialfissionand pages 7-8): Mode Al Ojaimi, Azza Salah, and Ayman El-Hattab. Mitochondrial fission and fusion: molecular mechanisms, biological functions, and related disorders. Membranes, 12:893, Sep 2022. URL: https://doi.org/10.3390/membranes12090893, doi:10.3390/membranes12090893. This article has 167 citations.

7. (weisschuh2021mutationspectrumof pages 17-18): Nicole Weisschuh, Simone Schimpf-Linzenbold, Pascale Mazzola, Sinja Kieninger, Ting Xiao, Ulrich Kellner, Teresa Neuhann, Carina Kelbsch, Felix Tonagel, Helmut Wilhelm, Susanne Kohl, and Bernd Wissinger. Mutation spectrum of the opa1 gene in a large cohort of patients with suspected dominant optic atrophy: identification and classification of 48 novel variants. PLoS ONE, 16:e0253987, Jul 2021. URL: https://doi.org/10.1371/journal.pone.0253987, doi:10.1371/journal.pone.0253987. This article has 37 citations and is from a peer-reviewed journal.

8. (nottia2021mitochondrialdynamicsmolecular pages 8-10): Michela Di Nottia, Daniela Verrigni, Alessandra Torraco, Teresa Rizza, Enrico Bertini, and Rosalba Carrozzo. Mitochondrial dynamics: molecular mechanisms, related primary mitochondrial disorders and therapeutic approaches. Genes, 12:247, Feb 2021. URL: https://doi.org/10.3390/genes12020247, doi:10.3390/genes12020247. This article has 57 citations.

9. (lee2024hereditaryopticneuropathies pages 5-7): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.

10. (dotto2021dominantopticatrophy pages 5-6): Valentina Del Dotto and Valerio Carelli. Dominant optic atrophy (doa): modeling the kaleidoscopic roles of opa1 in mitochondrial homeostasis. Frontiers in Neurology, Jun 2021. URL: https://doi.org/10.3389/fneur.2021.681326, doi:10.3389/fneur.2021.681326. This article has 23 citations and is from a peer-reviewed journal.

11. (strachan2025novelinvivo pages 1-2): Elin L. Strachan, Eugene T. Dillon, Mairéad Sullivan, Jeffrey C. Glennon, Amandine Peyrel, Jérôme Sarniguet, Kevin Dubois, Benjamin Delprat, Breandán N. Kennedy, and Niamh C. O'Sullivan. Novel in vivo models of autosomal optic atrophy reveal conserved pathological changes in neuronal mitochondrial structure and function. The FASEB Journal, Apr 2025. URL: https://doi.org/10.1096/fj.202403271r, doi:10.1096/fj.202403271r. This article has 1 citations.

12. (dotto2021dominantopticatrophy pages 10-11): Valentina Del Dotto and Valerio Carelli. Dominant optic atrophy (doa): modeling the kaleidoscopic roles of opa1 in mitochondrial homeostasis. Frontiers in Neurology, Jun 2021. URL: https://doi.org/10.3389/fneur.2021.681326, doi:10.3389/fneur.2021.681326. This article has 23 citations and is from a peer-reviewed journal.

13. (alavi2013dominantopticatrophy pages 1-3): Marcel V Alavi and Nico Fuhrmann. Dominant optic atrophy, opa1, and mitochondrial quality control: understanding mitochondrial network dynamics. Molecular Neurodegeneration, 8:32, Sep 2013. URL: https://doi.org/10.1186/1750-1326-8-32, doi:10.1186/1750-1326-8-32. This article has 178 citations and is from a highest quality peer-reviewed journal.

14. (fogazza2018biochemicalcharacterizationand pages 35-38): Mario Fogazza. Biochemical characterization and validation of a novel cellmodel for dominant optic atrophy. ArXiv, Apr 2018. URL: https://doi.org/10.6092/unibo/amsdottorato/8630, doi:10.6092/unibo/amsdottorato/8630. This article has 0 citations.

Artifacts

• Edison artifact artifact-00

Behr Syndrome: Comprehensive Disease Characteristics Report

Summary

Behr syndrome (OMIM #210000; MONDO:0008623; Orphanet ORPHA:1272) is a rare, childhood-onset, genetically heterogeneous neurodegenerative "optic-atrophy-plus" disorder. First described in 1909 by the ophthalmologist Carl Behr, it is defined by a clinical tetrad of early childhood-onset bilateral optic atrophy, cerebellar ataxia, pyramidal/spastic signs (spastic paraparesis), and peripheral (sensorimotor axonal) neuropathy, frequently accompanied by intellectual disability/learning difficulties, nystagmus, and ophthalmoparesis. Rather than a single-gene disease, Behr syndrome is best understood as a convergent clinical phenotype produced by biallelic/recessive loss-of-function variants in a set of mitochondrial or mitochondria-associated genes.

The molecular etiology is entirely genetic. Reported causal genes include biallelic OPA1 (mitochondrial fusion GTPase), C12orf65/MTRFR (mitochondrial translation release factor), OPA3 (Costeff syndrome / 3-methylglutaconic aciduria type III), C19orf12 (MPAN/NBIA), and UCHL1. Nearly all encode mitochondrial or mitochondria-associated proteins, and patient cells consistently show impaired oxidative phosphorylation (OXPHOS), fragmented mitochondria, and reduced oxygen consumption. The unifying pathomechanism is mitochondrial dysfunction and energy failure in high-demand neurons, with retinal ganglion cells (RGCs) being selectively vulnerable due to their high energy requirement and long, partly unmyelinated axons. Downstream axon degeneration proceeds through SARM1-dependent axon death, positioning SARM1 as a promising therapeutic node.

There is no disease-specific cure. Management is supportive and symptomatic (low-vision aids, physiotherapy for spasticity/ataxia, seizure and neuropathy management, genotype-guided surveillance such as cardiac follow-up in UCHL1-related disease). Emerging therapies from the broader mitochondrial optic neuropathy field—the antioxidant idebenone (a short-chain CoQ10 analogue that bypasses complex I) and gene-based therapies (allotopic expression, variant-agnostic gene-expression modulation)—are being explored for OPA1 disease. Prognosis is gene- and severity-dependent, ranging from near-normal lifespan with preserved ambulation beyond the fifth decade (OPA3/Costeff) to early death from intractable seizures, metabolic strokes, or hypertrophic cardiomyopathy (severe biallelic OPA1; UCHL1).

Key Findings

1. Disease Definition and Core Clinical Tetrad (F001)

Behr syndrome is a childhood-onset neurodegenerative disorder defined by optic atrophy accompanied by additional neurological signs. Across case series it is consistently described as a clinical tetrad: early childhood-onset bilateral optic atrophy, cerebellar ataxia, pyramidal/spastic signs (spastic paraparesis), and peripheral sensorimotor axonal neuropathy, often with intellectual disability/learning difficulties, nystagmus, and ophthalmoparesis.

"Behr syndrome, first described in 1909 by the ophthalmologist Carl Behr, is a clinical entity characterised by a progressive optic atrophy, ataxia, pyramidal signs and mental retardation." — PMID: 26187298

"Behr's syndrome is a classical phenotypic description of childhood-onset optic atrophy combined with various neurological symptoms, including ophthalmoparesis, nystagmus, spastic paraparesis, ataxia, peripheral neuropathy and learning difficulties." — PMID: 26380172

2. Genetic Heterogeneity with a Shared Mitochondrial Pathomechanism (F002)

Behr syndrome is genetically heterogeneous, but its causal genes converge mechanistically. Reported genes include biallelic OPA1, C12orf65/MTRFR, OPA3, C19orf12, and UCHL1. Nearly all encode mitochondrial or mitochondria-associated proteins. Patient cell lines demonstrate impaired oxidative phosphorylation, reduced OPA1 protein, fragmented mitochondria, and reduced oxygen consumption—a shared cellular signature of mitochondrial energetic failure.

"Some reported cases have been found to carry mutations in the OPA1, OPA3 or C12ORF65 genes which are known causes of pure optic atrophy or optic atrophy complicated by movement disorder." — PMID: 26187298

"C12orf65 (chromosome 12 open reading frame 65) gene encodes a mitochondrial matrix protein essential for the release of newly synthesized proteins from mitochondrial ribosomes. Biallelic pathogenic variants result in loss of function in the protein complex necessary for oxidative phosphorylation." — PMID: 40993840

The C12orf65/MTRFR form additionally implicates disturbed mitochondrial translation as a route to the same OXPHOS deficit (PMID: 26380172).

3. Biallelic OPA1 Causes Severe Early-Onset Behr Syndrome with Metabolic Strokes (F003)

While monoallelic OPA1 variants cause classic autosomal dominant optic atrophy (DOA, MIM 605290), biallelic (compound heterozygous/homozygous) OPA1 variants cause the severe syndromic Behr phenotype. By 2022, roughly 21 biallelic OPA1-Behr cases had been reviewed, all sharing an early-onset, severe ocular phenotype plus systemic features. Additional manifestations include congenital cataract, sensorimotor axonal polyneuropathy, intractable seizures / super-refractory status epilepticus, and stroke-like/metabolic stroke episodes with elevated lactate. A recurrent second allele, p.Ile382Met, is asymptomatic alone and acts as a phenotypic modifier.

"A biallelic mode of inheritance causes syndromic DOA or Behr phenotype, MIM # 605290." — PMID: 35741767

"Twenty-one cases have been previously reported. All share an early-onset, severe ocular phenotype and systemic features, which seem to be the hallmark of the disease." — PMID: 35741767

"The co-occurrence of bi-allelic mutations can explain the severity and the early onset of her disease." — PMID: 30972688

4. OPA3-Related Costeff Syndrome: A Behr-Overlapping Founder Disorder (F004)

Costeff syndrome (OPA3-related 3-methylglutaconic aciduria type III) is an autosomal-recessive neurodegenerative disorder that overlaps clinically with Behr syndrome: early-onset bilateral optic atrophy with choreoathetosis, later ataxia and spastic paraparesis, plus elevated urinary 3-methylglutaconic and 3-methylglutaric acid. It is prevalent among Iraqi Jews via a founder splice mutation c.143-1G>C. Natural-history data (n=28) show first signs in infancy/early childhood; ataxia and chorea dominate in childhood and are relatively stable, whereas pyramidal dysfunction appears later and progresses with age (r=0.71, p<0.001). The majority remain ambulatory beyond the fifth decade, and cognition is generally intact/low-average.

"Costeff syndrome (CS) is a rare autosomal-recessive neurological disorder, which is known almost exclusively in patients of Iraqi Jewish descent, manifesting in childhood with optic atrophy, ataxia, chorea and spastic paraparesis." — PMID: 25201222

"Pyramidal dysfunction appeared later and progressed with age (r = 0.71, p < 0.001) leading to spastic paraparesis and marked gait impairment." — PMID: 25201222

"Costeff syndrome or OPA3-related 3-methylglutaconic aciduria is an autosomal recessive neurodegenerative disorder characterized by early onset optic atrophy and choreoathetosis with later onset of ataxia and spasticity." — PMID: 26190011

5. RGC Degeneration Proceeds via Mitochondrial Dysfunction and SARM1-Dependent Axon Death (F005)

OPA1 encodes a dynamin-related inner-membrane GTPase controlling mitochondrial fusion, cristae structure, OXPHOS, mtDNA maintenance, calcium homeostasis, and apoptosis. Retinal ganglion cells are selectively vulnerable owing to their high energy demand and long, unmyelinated intraretinal axons. Critically, mouse Opa1 models (e.g., Opa1^R290Q/+) recapitulate mitochondrial defects, age-related RGC loss, and optic nerve degeneration, and SARM1 knockout nearly completely suppresses degeneration without reversing mitochondrial fragmentation—placing SARM1 downstream of the mitochondrial defect as the executioner of axon death. ADOA mutant neurons additionally show impaired fusion, loss of membrane potential, cytochrome c release, sustained intracellular Ca²⁺ rise, and mitophagy.

"Sarm1 KO nearly completely suppressed all the degeneration phenotypes without reversing mitochondrial fragmentation." — PMID: 40344041

"OPA1 encodes a dynamin-related GTPase imported into mitochondria and located to the inner membrane and intermembrane space." — PMID: 33340656

"LHON and DOA are both characterized by selective neurodegeneration of retinal ganglion cells (RGCs) triggered by mitochondrial dysfunction." — PMID: 36813316

6. No Cure Exists; Management Is Supportive with Emerging Therapies (F006)

Treatment of Behr syndrome and related mitochondrial optic neuropathies is largely supportive/symptomatic (low-vision aids, physiotherapy/rehabilitation for spasticity and ataxia, seizure and neuropathy management). For the broader disease class, idebenone—a short-chain CoQ10 analogue/antioxidant that bypasses complex I—is approved in Europe for LHON and has been tried in OPA1-DOA. Gene therapy (allotopic expression) reached Phase III for LHON, and variant-agnostic gene-expression-modulation trials are underway for OPA1-DOA. Other agents (antioxidants, anti-apoptotic drugs, mitobiogenesis activators) remain at Phase II/preclinical stages. Avoidance of mitochondrial toxins (certain drugs, tobacco/alcohol) is advised.

"Clinical trials for LHON have demonstrated the efficacy of idebenone, an oral neuroprotective agent, and gene replacement therapy using allotopic gene expression. Early phase clinical trials are underway for ADOA caused by variants in the nuclear gene OPA1 using innovative techniques to modulate gene expression in a variant-agnostic manner." — PMID: 41318849

"The successful launch of the antioxidant idebenone for Leber's Hereditary Optic Neuropathy (LHON), followed by its introduction into clinical practice across Europe, was an important step forward." — PMID: 33159657

7. Ultra-Rare Recessive Disorder with Founder Effects and Consanguinity Contribution (F007)

Behr syndrome has no precise prevalence estimate (Orphanet lists it as a rare disease; fewer than ~25 biallelic OPA1 cases reported by 2022). It sits within the mitochondrial optic neuropathy spectrum: autosomal dominant optic atrophy, the parent disorder for OPA1, has prevalence ~1/10,000 in Denmark (founder effect) and ~1/30,000–1/50,000 elsewhere, with ~20% showing syndromic "plus" features. Behr syndrome forms are inherited autosomal recessively (biallelic OPA1, C12orf65, C19orf12, UCHL1) or AR (OPA3/Costeff, an Iraqi-Jewish founder disorder). Consanguinity increases the risk of homozygous recessive forms.

"The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000 in the rest of the world." — PMID: 22776096

"About 20% of DOA patients harbour extraocular multi-systemic features" — PMID: 22776096

8. Animal and Cellular Models Recapitulate Behr-Spectrum Pathology (F008)

Multiple models reproduce the disease's mitochondrial pathology. The Opa1^R290Q/+ mouse recapitulates ADOA (mitochondrial defects, age-related RGC loss, optic nerve degeneration, reduced RGC function). The Opa3^L122P mouse (Costeff model) shows disrupted mitochondrial function impairing skeletal integrity. Patient-derived iPSCs (iPS-OPA1-BEHR) were generated from compound-heterozygous OPA1 fibroblasts for disease modeling, and patient fibroblasts show increased fragmented/intermediate mitochondria under galactose stress and reduced OPA1 protein. C. elegans and zebrafish (Danio rerio) are used for OPA1/mitophagy studies and idebenone/QS10 rescue experiments. Orthologous genes are conserved across vertebrates (mouse Opa1, Opa3).

"We generated a mouse model carrying the pathogenic Opa1R290Q/+ allele that recapitulated key features of human ADOA, including mitochondrial defects, age-related RGC loss, optic nerve degeneration, and reduced RGC functions." — PMID: 40344041

"The generated iPS-OPA1-BEHR line might be a useful platform to study the pathomechanism of early onset complicated optic atrophy syndromes." — PMID: 27879217

9. Phenotype Spectrum with HPO Terms and Variable Expressivity (F009)

Core, near-obligate features and their HPO terms include: bilateral optic atrophy (HP:0000648) with childhood-onset progressive visual loss/reduced visual acuity (HP:0000505, HP:0007766), cerebellar/gait ataxia (HP:0001251, HP:0002066), spasticity/spastic paraparesis (HP:0001257, HP:0002061), pyramidal signs (hyperreflexia, HP:0001347), peripheral sensorimotor axonal neuropathy (HP:0007141/HP:0003477), and intellectual disability/learning difficulties (HP:0001249). Frequent/variable features: nystagmus (HP:0000639), ophthalmoparesis/strabismus (HP:0000602/HP:0000486), dysarthria (HP:0001260), dystonia/choreoathetosis (HP:0001332/HP:0001266, esp. OPA3), congenital cataract (HP:0000519), scoliosis (HP:0002650), seizures (HP:0001250), tremor (HP:0001337). Rare/severe features: metabolic stroke-like episodes with elevated lactate (HP:0001943/HP:0002151), hypertrophic cardiomyopathy (HP:0001639, UCHL1), multiorgan failure and early death (severe biallelic OPA1). OPA3/Costeff adds 3-methylglutaconic aciduria (HP:0003535). Expressivity is highly variable even within families.

"childhood-onset optic atrophy combined with various neurological symptoms, including ophthalmoparesis, nystagmus, spastic paraparesis, ataxia, peripheral neuropathy and learning difficulties" — PMID: 26380172

"two unrelated sporadic girls manifesting a spastic ataxic syndrome associated with peripheral neuropathy and, only in one, optic atrophy" — PMID: 28494813

"In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death" — PMID: 32656641

10. Diagnosis: Clinical Recognition Plus NGS, with Supportive Testing (F010)

Molecular diagnosis is established by gene panel testing or whole-exome/whole-genome sequencing (targeted mitochondrial-disorder panels of ~132 genes and trio-WES have identified causal OPA1, C12orf65, OPA3, C19orf12, UCHL1 variants). Supportive tests include: ophthalmology (fundoscopy showing optic disc pallor, OCT showing RNFL/ganglion-cell-layer thinning, visual fields, VEP); brain MRI (cerebellar atrophy, basal ganglia signal changes, Leigh-like lesions, elevated lactate peak on MRS); nerve conduction studies/EMG confirming axonal sensorimotor polyneuropathy; muscle biopsy (reduced cytochrome c oxidase staining, ragged-red-type changes) and biochemical OXPHOS assays; and urine organic acids (elevated 3-methylglutaconic and 3-methylglutaric acid in OPA3/Costeff). Chromosomal microarray may reveal contributory copy-number changes (e.g., a 3q deletion co-occurring with OPA1).

"The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing." — PMID: 32656641

"muscle biopsy showed diffuse reduction of cytochrome c oxidase stain" — PMID: 28442211

"Magnetic resonance imaging of the brain showed bilateral hypointense signals in the basal ganglia which prompted us to consider neurodegeneration with brain iron accumulation (NBIA) as a differential diagnosis." — PMID: 26187298

11. Chronic Progressive Course; Prognosis Varies by Gene and Severity (F011)

Onset is typically infancy to early childhood with an insidious, chronic-progressive course. Anatomical involvement spans the eye/optic nerve (retinal ganglion cells CL:0000740; optic nerve UBERON:0000941; retina UBERON:0000966), cerebellum (UBERON:0002037), corticospinal/pyramidal tracts and spinal cord (UBERON:0002240), basal ganglia (UBERON:0002420), peripheral nerves (UBERON:0001021), and skeletal muscle (UBERON:0001134) in severe forms; the subcellular target is the mitochondrion (GO:0005739; inner membrane GO:0005743). Prognosis is gene- and severity-dependent: OPA3/Costeff patients often remain ambulatory beyond the fifth decade with intact cognition and near-normal lifespan, whereas severe biallelic OPA1 cases show early-onset severe visual loss, intractable seizures, metabolic strokes, and possible early death/multiorgan failure. A UCHL1 family died of hypertrophic cardiomyopathy/sudden cardiac death at ages 40–43. Visual impairment is generally permanent (often legally blind); motor disability accrues over decades.

"The course of neurological deterioration was slow and the majority of patients could still walk beyond the fifth decade." — PMID: 25201222

"died of sudden cardiac death at age 43 and 40, respectively" — PMID: 32656641

12. Identifiers, Synonyms, and Purely Genetic Etiology (F012)

Identifiers: OMIM #210000 (Behr syndrome / optic atrophy plus); related OMIM entries — OPA1 605290, OPA3/Costeff (3-MGA type III) 258501, COXPD7/C12orf65 613559, MPAN/C19orf12 614298; Orphanet ORPHA:1272; MeSH "Optic Atrophy, Hereditary, Behr"/"Behr syndrome"; MONDO:0008623; ICD-10 H47.2 (optic atrophy)/G31.8; ICD-11 9C40.

Synonyms: "optic atrophy, infantile, with ataxia and spasticity," "optic atrophy-ataxia syndrome," "Behr complicated optic atrophy," "early-onset optic atrophy plus."

Etiology is entirely genetic (biallelic/recessive OPA1, C12orf65/MTRFR, OPA3, C19orf12, UCHL1; occasionally digenic/modifier contributions such as OPA1 p.Ile382Met/p.Ile437Met and co-occurring mtDNA variants). No infectious, toxic, or environmental cause is known; no established environmental or genetic protective factors exist. Information is derived from a mix of aggregated disease-level resources (OMIM/Orphanet) and individual case reports/small case series.

"Behr syndrome; OMIM #210000" — PMID: 27879217

"The mother, aunt, and grandmother are heterozygous for the Ile382Met mutation and are asymptomatic." — PMID: 30972688

13. Prevention Is Genetic (F013)

Because Behr syndrome is autosomal recessive with no environmental cause, primary prevention relies on genetic counseling for at-risk/consanguineous families and founder populations (e.g., Iraqi-Jewish OPA3 carrier testing for c.143-1G>C), carrier screening, cascade testing of relatives, and reproductive options including prenatal testing and preimplantation genetic diagnosis (PGD) once familial variants are known. Secondary prevention: early ophthalmologic and neurologic evaluation of affected sibs. Tertiary prevention: cardiac surveillance/echocardiography in UCHL1-related disease (hypertrophic cardiomyopathy risk), seizure management, physiotherapy/orthopedic management of spasticity and scoliosis, low-vision support, and avoidance of mitochondrial toxins. No newborn screening or vaccine is applicable.

"highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations" — PMID: 32656641

"Genetic testing of patients presenting with Behr syndrome should include C19ORF12 mutation screening." — PMID: 26187298

Detailed Section-by-Section Report

1. Disease Information

Behr syndrome is a childhood-onset, progressive neurodegenerative disorder characterized by the combination of bilateral optic atrophy with additional neurological deficits (ataxia, pyramidal/spastic signs, peripheral neuropathy, and cognitive impairment). It is not a single-gene entity but a convergent phenotype ("optic-atrophy-plus") arising from several mitochondrial-related genes.

• Key identifiers: OMIM #210000; MONDO:0008623; Orphanet ORPHA:1272; MeSH "Behr syndrome"/"Optic Atrophy, Hereditary, Behr"; ICD-10 H47.2/G31.8; ICD-11 9C40.
• Synonyms: optic atrophy–ataxia syndrome; infantile optic atrophy with ataxia and spasticity; Behr complicated optic atrophy; early-onset optic atrophy plus.
• Data source type: A mixture of aggregated disease-level resources (OMIM, Orphanet) and individual patient-level case reports/small case series—not EHR-derived population data.

2. Etiology

Causal factors: Entirely genetic. Behr syndrome results from biallelic (recessive) loss-of-function variants, most commonly in OPA1, along with C12orf65/MTRFR, OPA3, C19orf12, and UCHL1. Some cases involve modifier/digenic contributions (e.g., the hypomorphic OPA1 p.Ile382Met allele; co-occurring mtDNA variants; a concurrent 3q chromosomal deletion in one OPA1 case).

Genetic risk factors: Consanguinity and membership in founder populations (Iraqi Jews for OPA3 c.143-1G>C) raise recessive-disease risk. Carrier parents are typically asymptomatic.

Environmental risk factors / protective factors / gene–environment interactions: None established. No toxin, infection, lifestyle, or dietary factor is known to cause, prevent, or modify Behr syndrome, though avoidance of mitochondrial toxins (tobacco, alcohol, certain drugs) is advised on mechanistic grounds.

3. Phenotypes

See Finding 9 for the full HPO-annotated spectrum. In brief, the phenotype is dominated by early-childhood, progressive, bilateral, symmetric visual loss from optic atrophy (near-obligate), plus cerebellar ataxia, spastic paraparesis with pyramidal signs, sensorimotor axonal neuropathy, and intellectual disability. Onset is neonatal-to-early-childhood; severity ranges from mild (some OPA3/Costeff) to severe/lethal (biallelic OPA1, UCHL1). Progression is generally slow but relentless, with permanent visual impairment and accruing motor disability substantially reducing quality of life (mobility, independent living, education/employment, and—via blindness—daily functioning).

4. Genetic/Molecular Information

Variant classification: Reported variants are largely pathogenic/likely pathogenic (ACMG/AMP), often novel and private to families; many are absent from population controls (e.g., novel OPA1 compound heterozygous variants not seen in n=300 controls). Variant types span missense, frameshift, nonsense, splice-site, and structural/CNV (3q deletion). Allele frequencies are very low/absent in gnomAD for pathogenic alleles; the OPA1 p.Ile382Met modifier is more common and asymptomatic in heterozygotes. Origin is germline. Functional consequence is predominantly loss of function converging on OXPHOS deficiency; domain-specific OPA1 effects (GTPase vs. BSE) modulate fusion and apoptosis severity.

Modifier genes: OPA1 p.Ile382Met and co-occurring mtDNA variants modify severity. Epigenetics/chromosomal: No disease-specific epigenetic signature is established; a de novo 3q deletion co-occurring with an OPA1 missense variant produced a severe Behr-like phenotype.

5. Environmental Information

No environmental, lifestyle, or infectious agents are implicated in Behr syndrome causation. This is a monogenic mitochondrial disorder. The only environmental relevance is the advisory to avoid mitochondrial toxins that could exacerbate an already compromised OXPHOS system.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Biallelic LoF variant (OPA1 / C12orf65 / OPA3 / C19orf12 / UCHL1)
│
▼
Impaired mitochondrial fusion / translation / integrity
│
▼
OXPHOS deficiency → ATP failure, ↑ROS, cristae disruption,
   mtDNA instability, Ca²⁺ dysregulation, cytochrome c release
│
▼
Selective stress on high-demand neurons (retinal ganglion cells;
   long CNS/PNS axons)  ── mitochondrial fragmentation, mitophagy
│
▼
SARM1-dependent axon self-destruction (executioner step)
│
▼
RGC/axon loss → optic atrophy; cerebellar, corticospinal,
   peripheral-nerve degeneration → ataxia, spasticity, neuropathy

• Molecular pathways: Mitochondrial fusion/dynamics; mitochondrial translation; intrinsic apoptosis (cytochrome c/caspase); SARM1/NAD⁺ axon-death pathway; calcium-mediated mitophagy.
• Cellular processes: Apoptosis, mitophagy, oxidative stress, energy failure (GO:0006915 apoptotic process; GO:0000422 mitophagy; GO:0006119 oxidative phosphorylation; GO:0008053 mitochondrial fusion).
• Protein dysfunction: Loss of function of OPA1 GTPase; domain-specific defects (GTPase β-fold vs. BSE α-helix) differentially impair fusion, membrane-potential maintenance, and apoptosis.
• Metabolic changes: OXPHOS/complex I deficiency; elevated lactate (metabolic strokes, MRS peak); elevated urinary 3-methylglutaconic/3-methylglutaric acid (OPA3/Costeff).
• Cell types / compartments: Retinal ganglion cells (CL:0000740); neurons broadly; mitochondrion (GO:0005739) and inner mitochondrial membrane (GO:0005743).
• Immune involvement: None; this is a primary energetic/neurodegenerative disorder.

7. Anatomical Structures Affected

• Organ level: Eye/optic nerve (primary), brain (cerebellum, basal ganglia, corticospinal tracts), spinal cord, peripheral nerves; heart (UCHL1, HCM) and skeletal muscle (severe forms) as secondary/variable.
• Body systems: Visual/nervous system (central and peripheral), with cardiovascular involvement in the UCHL1 form.
• UBERON/CL terms: optic nerve UBERON:0000941; retina UBERON:0000966; retinal ganglion cell CL:0000740; cerebellum UBERON:0002037; spinal cord/corticospinal tract UBERON:0002240; basal ganglia UBERON:0002420; peripheral nerve UBERON:0001021; skeletal muscle UBERON:0001134.
• Subcellular: mitochondrion GO:0005739; inner membrane GO:0005743.
• Localization/laterality: Bilateral and largely symmetric optic and neurological involvement.

8. Temporal Development

• Onset: Congenital to early childhood; insidious, chronic.
• Progression: Slowly progressive; in Costeff, ataxia/chorea appear early and stabilize while pyramidal dysfunction appears later and worsens with age (r=0.71, p<0.001). Severe biallelic OPA1 can present acutely with status epilepticus/metabolic stroke episodes.
• Course: Chronic, lifelong; visual loss permanent. No spontaneous remission.
• Critical periods: Early childhood is the key window; therapeutic intervention (idebenone, gene therapy) is hypothesized to be most beneficial before extensive RGC loss.

9. Inheritance and Population

• Epidemiology: Ultra-rare; no precise prevalence. Fewer than ~25 biallelic OPA1-Behr cases by 2022. Parent disorder ADOA prevalence ~1/10,000 (Denmark, founder) to ~1/30,000–1/50,000 elsewhere; ~20% of ADOA is syndromic.
• Inheritance: Autosomal recessive/biallelic (OPA1, C12orf65, C19orf12, UCHL1); AR for OPA3/Costeff. Penetrance of biallelic genotypes is high; expressivity is highly variable. Heterozygous carriers are typically asymptomatic.
• Founder effects / consanguinity: OPA3 c.143-1G>C is an Iraqi-Jewish founder mutation; consanguinity increases recessive-disease risk.
• Demographics: Costeff concentrated in Iraqi Jews. No strong sex bias reported for Behr syndrome overall.

10. Diagnostics

See Finding 10. Diagnosis rests on clinical recognition of optic atrophy plus neurological signs, confirmed by gene panel/WES/WGS. Supportive workup: OCT (RNFL/GCL thinning), VEP, visual fields, fundoscopy; brain MRI/MRS (cerebellar atrophy, basal ganglia changes, Leigh-like lesions, lactate peak); NCS/EMG (axonal sensorimotor polyneuropathy); muscle biopsy (reduced COX staining) and OXPHOS assays; urine organic acids (3-MGA in OPA3); chromosomal microarray for CNVs. Key differential diagnoses: NBIA (basal ganglia iron), hereditary spastic paraplegias, other mitochondrial optic neuropathies (LHON, DOA), and spinocerebellar ataxias.

11. Outcome / Prognosis

Prognosis is gene- and severity-dependent. OPA3/Costeff: slow neurological deterioration, ambulation preserved beyond the fifth decade, intact-to-low-average cognition, near-normal lifespan. Severe biallelic OPA1: early severe visual loss, intractable seizures, metabolic strokes, possible multiorgan failure and early death. UCHL1: hypertrophic cardiomyopathy with sudden cardiac death (ages 40–43). Visual impairment is permanent (often legal blindness); morbidity accrues from progressive motor disability. Prognostic factors: causal gene, biallelic dosage/variant severity, age of onset, presence of seizures/metabolic strokes/cardiomyopathy.

12. Treatment

• Pharmacotherapy: No disease-specific drug. Idebenone (short-chain CoQ10 analogue, complex I bypass) used in the broader class; the metabolite QS10 restores respiration in complex I/CoQ defects in cellular and zebrafish models. Symptomatic drugs for seizures, spasticity, and neuropathic pain.
• Advanced therapeutics: Gene therapy (allotopic expression, Phase III in LHON); variant-agnostic gene-expression modulation trials underway for OPA1-DOA. SARM1 inhibition is a mechanistically supported preclinical target.
• Surgical/supportive/rehabilitative: Low-vision aids; physiotherapy/occupational/speech therapy; orthopedic management of scoliosis/spasticity; cardiac management in UCHL1 form.
• MAXO suggestions: pharmacotherapy (MAXO:0000058), gene therapy (MAXO:0000004), physiotherapy/rehabilitation (MAXO:0000506), surveillance/monitoring (MAXO:0000644), dietary/supportive care.

13. Prevention

Genetic prevention (counseling, carrier/cascade testing, prenatal diagnosis, PGD) is the mainstay, plus genotype-guided tertiary prevention (cardiac surveillance in UCHL1). No immunization, newborn screening, or behavioral prevention applies.

14. Other Species / Natural Disease

• Taxonomy/orthologs: Human genes have conserved orthologs — mouse Opa1, Opa3, C12orf65, Uchl1 (NCBI Taxon 10090); zebrafish Danio rerio (7955); C. elegans (6239).
• Natural disease: No well-documented naturally occurring Behr syndrome equivalent in companion animals/wildlife (OMIA not specifically implicated); disease knowledge comes from engineered models rather than natural animal disease.
• Comparative biology: Mitochondrial fusion/OXPHOS mechanisms are deeply evolutionarily conserved, underpinning the utility of cross-species models.
• Zoonotic potential: Not applicable (non-infectious genetic disease).

15. Model Organisms

Limitations: Most models capture mitochondrial/RGC pathology (dominant ADOA) rather than the full recessive multisystem Behr tetrad; the iPSC model is early-stage; no model fully reproduces the human seizure/metabolic-stroke/cardiomyopathy spectrum.

Mechanistic Model / Interpretation

Behr syndrome exemplifies phenotypic convergence from genetic heterogeneity: several distinct genes, all touching mitochondrial biology (fusion via OPA1, translation via C12orf65, outer-membrane integrity via OPA3, mitochondria-associated function via C19orf12, and protein homeostasis via UCHL1), produce a shared clinical picture because they all cause a cellular energy deficit that most severely afflicts the body's most metabolically demanding, longest-axon neurons. Retinal ganglion cells are the sentinel casualty (optic atrophy), followed by cerebellar, corticospinal, and peripheral-nerve degeneration.

The dosage principle is central: monoallelic OPA1 → dominant optic atrophy; biallelic OPA1 → syndromic Behr, with hypomorphic modifier alleles (p.Ile382Met) tuning severity. The recent demonstration that SARM1 knockout suppresses degeneration downstream of persistent mitochondrial fragmentation reframes therapy: even without correcting the primary mitochondrial defect, blocking the axon-death executioner may preserve neurons. This dovetails with the two clinically advanced strategies—idebenone (energetic rescue upstream) and gene therapy (correcting the primary lesion)—to define a three-tier therapeutic map: (1) fix the gene, (2) bypass/boost mitochondrial energetics, (3) block SARM1-mediated axon death.

Evidence Base

Supporting/contextual papers: OPA1 domain-specific defects PMID: 40275276; Ca²⁺-mediated mitophagy PMID: 34389813; idebenone metabolite QS10 PMID: 29694828; OPA1 recessive cataract/neuropathy case PMID: 27150940; OPA1 + 3q deletion PMID: 32883255; OPA3 neuro-ophthalmic phenotype PMID: 33870938; Costeff neuropsychology PMID: 25657044.

Limitations and Knowledge Gaps

1. No precise epidemiology. Behr syndrome prevalence/incidence is unknown; estimates are extrapolated from the parent ADOA disorder and small case counts (<25 biallelic OPA1 cases).
2. Definitional ambiguity. "Behr syndrome" is a clinical descriptor spanning multiple genes; boundaries with ADOA-plus, Costeff, MPAN, and other mitochondrial optic neuropathies are blurred, complicating annotation.
3. Variable expressivity obscures genotype–phenotype correlations, and some cases lack the "obligate" optic atrophy.
4. Model gaps. Existing models chiefly capture dominant ADOA/RGC pathology; none fully reproduces the recessive multisystem Behr tetrad or the severe seizure/metabolic-stroke/cardiomyopathy manifestations.
5. No disease-specific trials. Therapeutic evidence (idebenone, gene therapy, SARM1) is borrowed from LHON/ADOA; efficacy in Behr syndrome specifically is unproven.
6. Limited omics. No transcriptomic/proteomic/metabolomic profiling specific to Behr-syndrome patient tissue beyond fibroblast/iPSC OXPHOS assays.

Proposed Follow-up Experiments / Actions

1. Establish an international Behr-syndrome registry with harmonized gene panels to derive real prevalence, gene-frequency, and natural-history data.
2. Deep phenotyping + longitudinal OCT/MRS to define gene-specific progression biomarkers (e.g., RNFL/GCL thinning rates; lactate dynamics) suitable as trial endpoints.
3. Test SARM1 inhibitors in the Opa1^R290Q/+ mouse and biallelic-OPA1 iPSC-RGC organoids to determine whether axon-death blockade preserves vision independent of mitochondrial correction.
4. Genotype-stratified idebenone/QS10 trials in biallelic-OPA1 and C12orf65 Behr patients, prioritizing early (pre-severe-loss) intervention windows.
5. Systematic cardiac and metabolic-stroke surveillance protocols, particularly UCHL1 (echocardiography) and biallelic OPA1 (lactate, seizure monitoring), to reduce mortality.
6. Multi-omics of patient iPSC-derived neurons (transcriptomics/proteomics/metabolomics) to identify convergent, druggable nodes across the heterogeneous genetic causes.
7. Expand carrier screening in founder/consanguineous populations (Iraqi-Jewish OPA3 c.143-1G>C) with reproductive counseling and PGD access.

Report compiled from 13 confirmed findings and 33 reviewed papers across 5 investigation iterations. Evidence sources span human clinical case series, model-organism studies (mouse, zebrafish, C. elegans), in vitro/iPSC work, and aggregated disease-level resources (OMIM, Orphanet).

Artifacts

• OpenScientist final report
• OpenScientist final report